Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023

Logo PR Newswire
PR Newswire

Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.

SAN DIEGO, Jan. 23, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs, will be presenting at the Emerging Growth Conference on January 25, 2023 (

This live interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO, Dr. David Koos, in real time. Please ask your questions during the event and Dr. Koos and his team will do their best to address as many of them as possible.

"We plan to use this time to update our stakeholders on recent intellectual property and answer shareholder questions," says Dr. David Koos, CEO and Chairman of the Company.

Regen BioPharma, Inc. will be presenting from 3:30 - 3:40 Eastern time on Wednesday, January 25, 2023. Please register here to ensure you are able to attend the conference and receive any updates that are released

If attendees are unable to join the event live on the day of the conference an archived webcast will also be made available on

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.

About Regen BioPharma Inc.:

Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at

Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax

Follow us on Twitter for future updates:

Cision View original content:

SOURCE BAP & Associates Limited

Logo PR Newswire
HealthPress Release2023-01-20 21:10:00
Company Expands on Issued Patent to Create Novel Approach to Selectively Killing Tumor Cells SAN DIEGO, Jan. 20, 2023 /PRNewswire/ -- Regen BioPharma, Inc....

Logo PR Newswire
HealthPress Release2023-01-23 12:05:00
- Company has initiated Phase I/II AFFINITY DUCHENNE ™ trial of RGX-202 - Company also enrolling newly active observational screening study, AFFINITY BEYOND,...

Logo EIN Presswire
HealthPress Release2023-01-23 13:38:17
Emergen Research Logo Increasing number of drug relapse and drug resistance cases and application of QSP in drug development processes are some key factors...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-23 12:05:00
- Company has initiated Phase I/II AFFINITY DUCHENNE trial of RGX-202 - Company also enrolling newly active observational screening study, AFFINITY BEYOND,...

Logo GlobeNewswire
SciencePress Release2023-01-23 08:10:00
Newton Biocapital II Leads Funding Round For First-of-Its-Kind Drug to Treat Insulin Resistance First Breakthrough Addressing Insulin Resistance in Type 2...

Logo PR Newswire
HealthPress Release2023-01-23 13:18:00
NEW YORK and JERUSALEM, Jan. 23, 2023 /PRNewswire/ -- Immunyx Pharma, a developer of immune modulating therapies for neutrophil based diseases, announced it...

Logo GlobeNewswire
SciencePress Release2023-01-23 12:00:00
Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ET BEDMINSTER, N.J., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Matinas...

Logo GlobeNewswire
SciencePress Release2023-01-23 12:30:00
LEXINGTON, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (iSpecimen or the Company), an online global marketplace that connects...

Logo EIN Presswire
HealthPress Release2023-01-23 11:20:06
Douglas Insights Copernicus Therapeutics; Moderna Inc., Wave Life Sciences; Protagonist Therapeutics; Transgene are some of the major key players. ISLE OF...

Logo EIN Presswire
HealthPress Release2023-01-23 11:44:17
Emergen Research Logo According to Emergen Research the market is expected to grow USD 38.79 billion by 2027, exhibiting a CAGR of 10.2% during the forecast...

Logo PR Newswire
HealthPress Release2023-01-23 13:00:00
-- FDA grants priority review and sets PDUFA action date of May 22, 2023 -- CAMBRIDGE, Mass., Jan. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation...

Logo NewsFileCorp
Press Release2023-01-23 14:37:00
Calgary, Alberta--(Newsfile Corp. - January 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to...

Logo PR Newswire
HealthPress Release2023-01-23 12:00:00
DALLAS, Jan. 23, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative...

Logo Nasdaq
Business / FinanceBy Rtt News2023-01-23 13:22:13
(RTTNews) - Blueprint Medicines Corporation (BPMC) announced the FDA has accepted the company's supplemental new drug application for AYVAKIT for the...

Logo PR Newswire
HealthPress Release2023-01-23 12:00:00
PRINCETON, N.J., Jan. 23, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the...

Logo Nasdaq
Business / FinanceBy Mt Newswires2023-01-23 14:13:11
Health care stocks were steady premarket Monday, with the Health Care Select Sector SPDR Fund ( XLV ) and the iShares Biotechnology ETF (IBB) unchanged....

Logo GlobeNewswire
SciencePress Release2023-01-23 11:00:00
VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF), an autologous stem cell therapy company, has...

Logo EIN Presswire
HealthPress Release2023-01-23 09:00:00
contextflow Chief Commercial Officer Marcel Wassink and Medexprim CEO Medexprim and contextflow are proud to announce their partnership

Logo EIN Presswire
Emergen Research Logo Limited entry barriers resulting in the entry of players of different tiers is a key factor driving biostimulants market revenue growth...

Logo PR Newswire
NEW YORK, Jan. 23, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has...